Dennis Bang Henriksen

This inventor holds 8 USPTO granted patents, plus 1 CIPO patent and 4 EPO patents. Top assignees: Sanos Bioscience A/s, Egetis Therapeutics Ab, Nordic Bioscience Dagnostics A/s. Active years: 2004-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dennis Bang Henriksen. Retrieved from https://idiyas.com/inventor/dennis-bang-henriksen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8

% Patents Active = 25.0

CIPO Patents = 1

EPO Patents = 4 (Patent Applications = 1)

Average Co-Inventor Count = 2.2

ph-index = 3

Forward Citations = 101(Granted Patents)

Location History:

Alleroed, DK (2004 - 2009)
Allerød, DK (2008 - 2022)

Company Filing History:

Egetis Therapeutics Ab

patents

1 out of 1

Nordic Bioscience Dagnostics A/s

patent

4. 1 out of 1

Nordic Bioscience Diagnostics A/s

patent

Years Active: 2004-2025

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12303516 - Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions (2025-05-20),

2. 11260060 - Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions (2022-03-01),

3. 7632684 - Assay of isomerised and/or optically inverted proteins and protein fragments (2009-12-15),

4. 7371721 - Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes (2008-05-13),

5. 7354723 - Assay of isomerised and/or optically inverted proteins and protein fragments (2008-04-08),

6. 7186683 - Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders (2007-03-06),

7. 6943151 - Method of inhibiting bone resorption and/or promoting bone formation using GLP-2 and related compounds (2005-09-13),

8. 6770620 - Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders (2004-08-03),

Title: Innovations by Dennis Bang Henriksen

Introduction

Dennis Bang Henriksen is a notable inventor based in Alleroed, Denmark. He has made significant contributions to the field of hepatotoxicity treatment, holding a total of 8 patents. His work focuses on developing methods and formulations aimed at treating and protecting against acute liver failure and other related conditions.

Latest Patents

Henriksen's latest patents include innovative methods for treating and protecting against acute liver failure. One of his notable inventions employs a combination of a first active agent, N-acetylcysteine, and a second active agent, a manganese complex. This manganese complex can be a calcium manganese mixed metal complex of N,N'-bis-(pyridoxal-5-phosphate)-ethylenediamine-N,N′-diacetic acid (DPDP) with a specific molar ratio of calcium to manganese. Other formulations involve mixtures of manganese DPDP and non-manganese-containing compounds, showcasing his commitment to advancing medical treatments.

Career Highlights

Throughout his career, Henriksen has worked with several prominent companies, including Sanos Bioscience A/S and Egetis Therapeutics AB. His experience in these organizations has allowed him to refine his expertise in the development of pharmaceutical solutions.

Collaborations

Henriksen has collaborated with notable professionals in his field, including Jens Juul Holst and Jacques Näsström. These partnerships have contributed to the advancement of his research and innovations.

Conclusion

Dennis Bang Henriksen is a distinguished inventor whose work in hepatotoxicity treatment has led to significant advancements in medical science. His innovative patents and collaborations reflect his dedication to improving health outcomes for individuals facing acute liver conditions.

Profile summary based on public USPTO records.